188Re DD-3B6/22 Fab' for use in therapy of ovarian cancer: labelling and animal studies.
A fast and high yielding method of 188Re radiolabelling DD-3B6/22 Fab' is described. An inert atmosphere [N2(g)] and ascorbic acid was essential for preparation and storage of therapeutic levels (< or =2 GBq/mg) for up to 24 h. Immunoreactivity was greater than 75%. Pharmacokinetic studies in nu/nu mice demonstrated localisation of 188Re DD-3B6/22 Fab' was equivalent and correlated well with the behaviour observed for 99mTc DD-3B6/22 Fab' used to image ovarian cancer. Excellent stability at the target site in vivo supports the potential use of 188Re DD-3B6/22 Fab' in the therapy of ovarian cancer.
Schmidt
P F
PF
Radiopharmaceutical Division Research and Development, Australian Nuclear Science and Technology Organisation (ANSTO), Menai, NSW.
Smith
S V
SV
Bundesen
P G
PG
D000818:Animals; D001205:Ascorbic Acid / Q000737:chemistry; D005260:Female; D005942:Gluconates / Q000737:chemistry; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry* / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D010084:Oxidation-Reduction; D016719:Radioimmunodetection; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D011878:Radiotherapy / Q000379:methods*; D012211:Rhenium / Q000737:chemistry; D013667:Technetium / Q000737:chemistry
D005942:Gluconates; D007140:Immunoglobulin Fab Fragments; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D012211:Rhenium; D013667:Technetium; D001205:Ascorbic Acid; C030691:gluconic acid